What Histocell SL does

Histocell SL is a Spanish biopharmaceutical company headquartered in Derio (Bizkaia) that develops, manufactures, and commercializes regenerative medicine products across four interconnected business units. Its core technology relies on adipose-derived adult mesenchymal stem cells and proprietary biomaterials, including the patented HC016 cell therapy platform for conditions such as acute respiratory distress syndrome and traumatic spinal cord injury, alongside an exosome manufacturing platform and 3D-printable Wharton Gel Complex bioinks. Operations are anchored by an AEMPS-authorized, GMP-certified 800 sqm manufacturing plant in Larrabetzu that supports treatment of up to 1,200 patients per year.

The company monetizes through multiple streams: clinical development and licensing of ATMPs (one-time license style for cell therapy drugs and biological medicines), GMP-grade CDMO services to pharmaceutical and biotech clients (quote-based multi-year contracts, including the REPROCELL iPSC partnership), sales of wound care medical devices led by Reoxcare (distributed via channel partner Cardiva across Spain and through international distributors in five additional countries), and direct-to-consumer e-commerce of dermocosmetics through shop.histocell.com. Pricing is quote-based for cell therapy drugs and CDMO, and per-unit for dermocosmetics.

Histocell sells primarily to hospital systems and intensive care units (Osakidetza, Osasunbida, Cruces Hospital/Biocruces Bizkaia), pharmaceutical and biotech companies (REPROCELL, Ferrer Pharmaceuticals for spinal cord injury), and indirectly to wound care and dermatology patients. It is privately held, part of the Grupo Noraybio group alongside Artinvet S.L., with corporate investors REPROCELL Inc. (TYO: 4978) and Cardiva on the cap table, and is led by CEO Julio Font and co-founder/CSO Begoña Castro. The company holds more than 50 patents in major world markets, has executed 40+ national and 9 European Framework Programme R&D projects, and employs approximately 30 multidisciplinary professionals.

Name

Histocell SL

Legal name

Histocell, S.L.

Website

https://histocell.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Histocell SL is a Derio, Spain-based biopharmaceutical company that develops adipose-derived stem cell therapies (HC016), wound care medical devices (Reoxcare), dermocosmetics, and GMP-grade CDMO services for pharmaceutical clients across Europe and LATAM.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)

akta.pro secondary industries

Cell Therapy CDMO (HLAGABAD), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)

Keywords

• Regenerative medicine
• Cell therapy drugs
• CDMO manufacturing services
• Wound healing devices
• Dermocosmetic products

Headquarters

HQ city

Derio

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Cell Therapy Drugs: Development and sale of proprietary cell therapy medicinal products including HC016 for treatment of Acute Respiratory Distress and spinal cord injury. Revenue from clinical development and eventual commercialization of ATMPs.
2. CDMO Services: Contract development and manufacturing organization offering GMP-grade manufacturing services for cell therapy products, biological medicinal products (secretomes, exosomes, CAR-T drugs), and medical devices to third-party clients.
3. Medical Devices - Wound Care: Sale of medical device products including Reoxcare for wound healing. Distributed through channel partners across Spain and internationally.
4. Dermo-cosmetics: Sale of dermo-cosmetic products through e-commerce including Histoessence Booster, Wharton Gel Complex, Reoxderm Liquid, and Reoxderm Cleanse.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Histocell is a biopharmaceutical company that develops, manufactures, and commercializes regenerative medicine products spanning four pillars: Advanced Therapy Medicinal Products (cell therapy drugs such as HC016 for ARDS and spinal cord injury plus biological drugs based on secretomes and exosomes); CDMO services providing GMP-grade contract manufacturing of cell therapy products, exosomes, secretomes, and CAR-T drugs for third-party pharma and biotech clients; wound-healing medical devices (Reoxcare) using antioxidant technology; and a dermo-cosmetic product line. Manufacturing is conducted at two AEMPS-authorized GMP facilities in Derio and Larrabetzu, Spain.

Product overview

Histocell SL is a biopharmaceutical company specializing in regenerative medicine with four interconnected business units: (1) Cellular and Biological Therapy Drugs including the patented HC016 cell therapy platform; (2) CDMO manufacturing services for advanced therapy medicinal products under GMP conditions; (3) Wound Healing medical devices led by the Reoxcare product line; and (4) Dermocosmetics including Histoessence Booster, Wharton Gel Complex, Reoxderm Liquid, and Reoxderm Cleanse. The company operates manufacturing facilities in Derio (Bizkaia Technology Park) and Larrabetzu, Spain.

Differentiator

Problem solved

Functional benefit

Brands

• Reoxcare: Antioxidant treatment of natural ingredients for healing of chronic wounds
• Histoessence Booster
• Wharton Gel Complex
• Reoxderm Liquid
• Reoxderm Cleanse

Products and services

• Cellular and Biological Therapy Drugs (ATMPs) Advanced Therapy Medicinal Products (ATMPs) including cell therapy drugs based on viable cells (e.g., HC016 for ARDS and acute-phase traumatic spinal cord injury) and biological medicines based on substances secreted by cells, such as secretomes and exosomes. Targeted at hospital and pharmaceutical buyers treating patients with unmet regenerative-medicine needs.
• CDMO Services Contract Development and Manufacturing Organization (CDMO) services providing GMP-grade manufacturing for advanced therapy medicinal products including cell therapies, exosomes, secretomes, and CAR-T drugs for third-party pharmaceutical, biotech, and iPSC clients (e.g., REPROCELL).
• Reoxcare Wound Healing Medical Device Antioxidant treatment of natural ingredients for the healing of chronic wounds, manufactured at the Larrabetzu medical-device plant under EU Regulation 2017/745. Sold to hospitals and healthcare systems (e.g., Osakidetza and Osasunbidea) through the Cardiva distribution partnership and international distributors.
• Histoessence Booster Dermo-cosmetic booster product for advanced skin care. Sold direct-to-consumer via Histocell's online shop across Spain (Peninsula €4 / Balearic €5 / Canary €10 shipping, free over 3 units).
• Wharton Gel Complex (WGC) Proprietary biomaterial dermo-cosmetic product and bioink foundation used in wound healing applications and 3D printable bioinks (WGC-HA) for advanced regenerative-medicine therapies.
• Reoxderm Liquid Dermo-cosmetic liquid product for skin treatment, sold direct-to-consumer via Histocell's online shop alongside other Reoxderm and Histoessence items.
• Reoxderm Cleanse Dermo-cosmetic cleansing product for skin care, sold direct-to-consumer via Histocell's online shop.

Quantifiable outcome

• Phase I clinical trial completed successfully with confirmed safety and signs of efficacy for HC016 in ARDS patients
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered minor and core.

• NABIHEAL ConsortiumminorStrategic or Co-development Partner · 9 January 2023European Horizon Europe project consortium developing antimicrobial nanostructured biomaterials for complex wound healing. Consortium includes 5 SMEs and 9 academic institutions. Histocell contributes REOXCARE technology expertise.
• FORCE REPAIR ConsortiumminorStrategic or Co-development Partner · 9 January 2023EU-funded project developing smart multifunctional 4D printable wound dressings for chronic wounds. 14 partners from 8 EU member states. Histocell contributes Wharton Gel Complex technology and 3D printable bioinks.
• REPROCELL Inc.coreStrategic or Co-development Partner · 23 November 2022Japanese biotech company REPROCELL invested in Histocell to strengthen its clinical iPSC service offerings. Histocell offers GMP-grade manufacturing services for cell therapy products while REPROCELL provides StemRNA Clinical iPSC Seed Clones compliant with FDA, EMA, and PMDA standards. In October 2025, both companies achieved GMP certification for manufacturing clinical-grade iPSC Master and Working Cell Banks.
• CardivacoreChannel Partner/ Reseller/ Distributor · 8 February 2021Distribution partnership for Reoxcare wound care product throughout the Spanish healthcare system. Cardiva distributes from its central warehouse in Lezama, strengthening Histocell's commercial capacity nationally.
• HEALIKICK ConsortiumminorStrategic or Co-development Partner · 1 June 2020Horizon 2020 project developing modular graft system for bone healing using granular graft material with osteogenic coating and pre-differentiated osteogenic MSCs. Histocell contributes GMP cell manufacturing expertise.
• Biocruces Bizkaia Health Research InstitutecoreStrategic or Co-development Partner · 1 May 2020Clinical trial collaboration for HC016 cell therapy drug testing in COVID-19 ARDS patients. The institute's ICU at Cruces Hospital served as the clinical trial site.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Lonza Cell & Gene Technologies: Global CDMO incumbent offering large-scale GMP manufacturing for cell and gene therapies, including autologous and allogeneic processes. Overlaps directly with Histocell's CDMO service line but at vastly greater scale and geographic reach.
• Mesoblast: Australia-listed commercial-stage cell therapy company with mesenchymal stem cell platforms targeting inflammatory and immune diseases, including ARDS. Comparable in modality (MSC therapies) and indication set to Histocell's pipeline.
• TiGenix (Takeda): Acquired by Takeda, TiGenix developed Cx601 (darvadstrocel), an approved adipose-derived stem cell therapy for complex perianal fistulas in Crohn's disease. Closely comparable adipose-derived MSC modality and wound/inflammatory indication focus to Histocell's HC016.
• Catalent (MaSTherCell): Catalent's cell therapy manufacturing business (including MaSTherCell in Belgium) is a leading ATMP CDMO serving North American and European biotechs. Directly comparable to Histocell's CDMO offering for cell therapies and biological medicinal products.

Direct peers

• RoslinCT: Scotland-based CDMO specializing in GMP manufacturing of cell therapies including iPSC-derived and mesenchymal stem cell products. Closely comparable in size, focus, and service portfolio to Histocell's CDMO business.
• CCRM: Canadian centre of excellence offering process development, GMP manufacturing, and commercialization services for cell and gene therapies, including iPSC platforms. Highly comparable in offering mix and academic/industry positioning to Histocell.
• CellGenix: Germany-headquartered manufacturer of GMP-grade raw materials, cytokines, and cell processing reagents for cell and gene therapy developers. Comparable to Histocell's ancillary cell processing capabilities and CDMO-adjacent product offering.
• REPROCELL: Japanese biotech (TYO: 4978) that is both an investor and active partner of Histocell, providing StemRNA Clinical iPSC Seed Clones and jointly achieving GMP certification for clinical-grade iPSC MCB/WCB. Direct overlap in GMP-grade cell therapy manufacturing and iPSC services for regenerative medicine.

Emerging players

• Athersys: US clinical-stage cell therapy company developing MultiStem for ARDS and other inflammatory indications. Direct therapeutic area overlap with Histocell's HC016 ARDS program, though operating at later clinical stage.

Others

• Cardiva: Spanish medical device distributor that is both a Histocell shareholder and exclusive Reoxcare distributor. Acts as a channel partner and strategic capital source rather than direct product competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Histocell SL